α-Synuclein-IN-21

α-Synuclein-IN-21 (Compound 3ec) (30 μM; 72 h) stabilizes the native random coil conformation of α-synuclein monomers and inhibits the formation of β-sheet-rich α-synuclein aggregates in vitro^[1].
α-Synuclein-IN-21 (30 μM; 96 h) inhibits the entire process of α-synuclein aggregation, with its core effect exerted during the lag phase by reducing oligomer nuclei, which decreases the apparent fibril growth rate constant to 0.124 h^−1[1].
α-Synuclein-IN-21 (30 μM; 88 h) inhibits the formation of large interconnected α-synuclein fibrils and reduces the size and density of aggregates^[1].
α-Synuclein-IN-21 (30 μM; 0-88 h) depolymerizes preformed α-synuclein aggregates and inhibits their re-aggregation, with the highest efficacy when administered during the lag phase of aggregation^[1].
α-Synuclein-IN-21 (10 μM; 38 h) inhibits the formation of α-synuclein inclusions in plasmid-transfected H4 cells^[1].
α-Synuclein-IN-21 (10 μM; 30 min) scavenges up to 70% of reactive oxygen species in H4 cells^[1].
α-Synuclein-IN-21 (1-100 μM; 24 h) exhibits low cytotoxicity in H4 and SH-SY5Y cells, maintaining over 85% cell viability even at concentrations up to 100 μM after 24 h of incubation^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.